Treatment of breast cancer during pregnancy: an observational study

Loibl, Sibylle, Han, Sileny N, von Minckwitz, Gunter, Bontenbal, Marijke, Ring, Alistair, Giermek, Jerzy, Fehm, Tanja, Van Calsteren, Kristel, Linn, Sabine C, Schlehe, Bettina, Gziri, Mina Mhallem, Westenend, Pieter J, Müller, Volkmar, Heyns, Liesbeth, Rack, Brigitte, Van Calster, Ben, Harbeck, Nadia, Lenhard, Miriam, Halaska, Michael J, Kaufmann, Manfred, Nekljudova, Valentina and Amant, Frederic (2012) Treatment of breast cancer during pregnancy: an observational study. The lancet oncology, 13 (9). pp. 887-896. ISSN 1474-5488

Full text not available from this repository.

Abstract

BACKGROUND

Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether treatment for breast cancer during pregnancy is safe for both mother and child.

METHODS

We recruited patients from seven European countries with a primary diagnosis of breast cancer during pregnancy; data were collected retrospectively if the patient was diagnosed before April, 2003 (when the registry began), or prospectively thereafter, irrespective of the outcome of pregnancy and the type and timing of treatment. The primary endpoint was fetal health for up to 4 weeks after delivery. The registry is ongoing. The study is registered with ClinicalTrials.gov, number NCT00196833.

FINDINGS

From April, 2003, to December, 2011, 447 patients were registered, 413 of whom had early breast cancer. Median age was 33 years (range 22-51). At the time of diagnosis, median gestational age was 24 weeks (range 5-40). 197 (48%) of 413 women received chemotherapy during pregnancy with a median of four cycles (range one to eight). 178 received an anthracycline, 15 received cyclophosphamide, methotrexate, and fluorouracil, and 14 received a taxane. Birthweight was affected by chemotherapy exposure after adjustment for gestational age (p=018), but not by number of chemotherapy cycles (p=71). No statistical difference between the two groups was observed for premature deliveries before the 37th week of gestation. 40 (10%) of 386 infants had side-effects, malformations, or new-born complications; these events were more common in infants born before the 37th week of gestation than they were in infants born in the 37th week or later (31 [16%] of 191 infants vs nine [5%] of 195 infants; p=0002). In infants for whom maternal treatment was known, adverse events were more common in those who received chemotherapy in utero compared with those who were not exposed (31 [15%] of 203 vs seven [4%] of 170 infants; p=00045). Two infants died; both were exposed to chemotherapy and delivered prematurely, but both deaths were thought not to be related to treatment. Median disease-free survival for women with early breast cancer was 76 months (95% CI 61-105) in women starting chemotherapy during pregnancy and 94 months (lower 95% CI 64; upper 95% CI not yet reached) in women starting chemotherapy after delivery (unadjusted hazard ratio 13 [95% CI 76-69]; p=539).

INTERPRETATION

Although our data show that infants exposed to chemotherapy in utero had a lower birthweight at gestational age than did those who were unexposed, and had more complications, these differences were not clinically significant and, since none of the infants was exposed to chemotherapy in the first trimester, were most likely related to premature delivery. Delay of cancer treatment did not significantly affect disease-free survival for mothers with early breast cancer. Because preterm birth was strongly associated with adverse events, a full-term delivery seems to be of paramount importance.

FUNDING

BANSS Foundation, Biedenkopf, Germany and the Belgian Cancer Plan, Ministry of Health, Belgium.

Item Type: Article
Additional Information: Impact Factor: 22.59
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: R Medicine
Related URLs:
Depositing User: Patricia Butler
Date Deposited: 19 Feb 2013 11:22
Last Modified: 19 Mar 2013 14:11
URI: http://sro.sussex.ac.uk/id/eprint/43791
📧 Request an update